Latest News & Features
article
April Weisbruch has joined McDermott Will & Emery as an IP partner, moving from Sheppard Mullin Richter & Hampton, where she worked as an IP associate. 3 March 2020
Americas
Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven. 2 March 2020
Big Pharma
The US Food and Drug Administration has revealed a COVID-19-related shortage of a drug, adding to concerns that the virus has the potential to massively disrupt medical supply chains. 2 March 2020
Big Pharma
UK-based pharmaceutical manufacturer Comb International, owner of the ‘Vagisil’ trademark, has successfully challenged the ‘Vagisan’ trademark at the Intellectual Property Office Singapore. 28 February 2020
Americas
The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling. 28 February 2020
Americas
California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics. 27 February 2020
Americas
Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus. 27 February 2020
Big Pharma
US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration. 27 February 2020
Big Pharma
French drugmaker Sanofi is looking to create a new European manufacturer of active pharmaceutical ingredients, amid concerns over dependence on a Chinese manufacturing sector hit by coronavirus. 27 February 2020
Americas
The US Court of Appeals for the Ninth Circuit has blocked generics makers’ request to halt California’s ban on pay-for-delay deals while they challenge the legislation. 25 February 2020